A patient with pulmonary arterial hypertension (PAH, Group 1) has WHO functional class III symptoms. Vasoreactivity testing with inhaled nitric oxide shows mean PAP decrease to 32 mmHg with cardiac output increase. What does this indicate?
-
A
Positive vasoreactivity test; candidate for long-term calcium channel blocker therapy
-
B
Negative vasoreactivity test; initiate combination prostanoid therapy
-
C
Indeterminate result; repeat test with adenosine
-
D
Positive test; proceed directly to lung transplant evaluation